Meaningful overhang from PROACT Xa trial discontinuation remains well in situ. Reasonable growth period in Q3, with revenue upsides from strengths in the core portfolio, including On-X contributions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback